Kiora Pharma Q1 net income $13.5M on $16M TOI revenue; $31.3M cash; KIO-301 Phase 2 on track

KIORA PHARMACEUTICALS INC

2024-Q1 EPS reported $0.38 revenue$16,000,000

Ended Q1 with $31.3M cash plus $1.8M R&D tax credits; runway over 2 years.
Revenue $16M from Théa Open Innovation upfront; net income $13.5M vs. $1.9M loss YoY.
Phase 2 ABACUS-2 trial for KIO-301 (retinitis pigmentosa) on track for Q4 2024 start.
Phase 2 trial for KIO-104 (retinal inflammation) expected to begin in 2025.
TOI deal includes up to $285M milestones and tiered royalties up to low-20% on sales.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

KIORA PHARMACEUTICALS INC reported the quarter ended March 31, 2024 results: revenue $16.0 million, net income $13.5 million.

Period: the quarter ended March 31, 2024
Revenue: $16.0 million
Net income: $13.5 million
Result: reported results

Exact text from the filing

Revenue was $16.0 million for the first quarter of 2024, compared to no revenue in the first quarter of 2023. The revenue comes from collaboration revenue as part of an upfront payment from TOI connected to the strategic development and commercialization partnership. Research and development expenses were $1.5 million, net of $0.2 million in offsetting credits related to expenses for KIO-301 which will be reimbursed by TOI, for the first quarter of 2024, compared to $0.4 million, net of $0.3 million in offsetting tax credits, for the first quarter of 2023. The increase was primarily due to a one-time licensing payment made to the University of California related to a sublicense fee of $0.7 million, and a decrease of $0.3 million in R&D tax credits due to reduced credit-eligible expenses given the KIO-301 expenses are now being reimbursed by TOI. General and administrative expenses were $1.3 million for the first quarter of 2024, compared to $1.3 million for the first quarter of 2023. N

View on SEC.gov

1050 earnings releases filed in the last 30 days. Browse all earnings releases →

KIORA PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001372514-24-000054

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.